Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.63 |
| ▸ | EBP | Q15125 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | ACR | P10323 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27663831 | 0.82 | FURIN (0.76) | FURINADRA2APRSS1ACRLTA4H | |
| SCHEMBL9706125 | 0.81 | EBP (0.72) | ADRA2AEBPSIGMAR1HTTCYP2D6 | |
| SCHEMBL27663840 | 0.79 | FURIN (0.77) | FURINADRA2APRSS1ACRCYP1A2 | |
| SCHEMBL13184915 | 0.79 | EBP (0.57) | ADRA2AEBPSIGMAR1HTTCYP2D6 | |
| SCHEMBL4099965 | 0.78 | ADRA2A (1.00) | FURINADRA2APRSS1ACRHTR3E | |
| SCHEMBL27663838 | 0.77 | FURIN (0.73) | FURINADRA2APRSS1ACRHTR3E | |
| SCHEMBL15976806 | 0.76 | EBP (0.62) | ADRA2AEBPSIGMAR1HTTCYP2D6 | |
| SCHEMBL4693255 | 0.76 | ESR1 (0.70) | EBPSIGMAR1HTTCYP2D6CYP1A2 | |
| SCHEMBL374223 | 0.76 | EBP (0.62) | EBPSIGMAR1HTTCYP2D6CYP1A2 | |
| SCHEMBL6812378 | 0.76 | EBP (0.67) | ADRA2AEBPSIGMAR1HTTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423388-B1 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-7078410-B2 | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders | ASTRAZENECA AB (SE) | 2006-07-18 | — | — | US | disclosed |
| US-6855719-B1 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives | ASTRAZENECA AB (SE) | 2005-02-15 | — | — | US | disclosed |
| US-20040106574-A1 | 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| EP-1423388-A2 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | AstraZeneca AB (SE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002066480-A2 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| EP-1214318-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106574-A1 | 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders | GSK3A, GSK3B, CKS2 | FURIN 4631/4885ADRA2A 3472/4885EBP 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.